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Abstract
Objective
Obesity is associated with changes in both right (RV) and left (LV) ventricular morphology,
but the biological basis of this finding is not well established. We examined whether adipo-
kine levels were associated with RV morphology and function in a population-based multi-
ethnic sample free of clinical cardiovascular disease.
Methods
We examined relationships of leptin, resistin, TNF-α, and adiponectin with RV morphology
and function (from cardiac MRI) in participants (n = 1,267) free of clinical cardiovascular dis-
ease from the Multi-Ethnic Study of Atherosclerosis (MESA)-RV study. Multivariable regres-
sions (linear, quantile [25th and 75th] and generalized additive models [GAM]) were used to
examine the independent association of each adipokine with RV mass, RV end-diastolic
volume (RVEDV), RV end-systolic volume (RVESV), RV stroke volume (RVSV) and RV
ejection fraction (RVEF).
Results
Higher leptin levels were associated with significantly lower levels of RV mass, RVEDV,
RVESV and stroke volume, but not RVEF, after adjustment for age, gender, race, height
and weight. These associations were somewhat attenuated but still significant after adjust-
ment for traditional risk factors and covariates, and were completely attenuated when cor-
recting for the respective LV measures. There were no significant interactions of age,
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Conclusions
Leptin levels are associated with favorable RV morphology in a multi-ethnic population free
of cardiovascular disease, however these associations may be explained by a yet to be
understood bi-ventricular process as this association was no longer present after adjust-
ment for LV values. These findings complement the associations previously shown
between adipokines and LV structure and function in both healthy and diseased patients.
The mechanisms linking adipokines to healthy cardiovascular function require further
investigation.
Introduction
Obesity is an increasingly common public health problem. As of 2010, 35.5% of adults in the
United States were obese [1], while 56.1% of adults met the metabolic syndrome criterion for
an elevated waist circumference [2]. Obesity has been independently associated with left ven-
tricular (LV) hypertrophy and dilation [3–5], and increasing body weight is associated with a
40 to 60% higher risk for incident heart failure [6, 7].
There are also significant implications of obesity in terms of right ventricular (RV) morpho-
logic and functional changes, but these have only been recognized more recently. Prior work
has shown that being overweight or obese is associated with increased RV mass and RV end-
diastolic volume (RVEDV) and lower RV ejection fraction (RVEF) in the Multi-Ethnic Study
of Atherosclerosis (MESA), independent of the respective LV parameter [8]. Others have
shown similar findings in smaller cohorts [9, 10].
Adipokines are bioactive proteins produced by the adipose compartment that have wide-
ranging effects across organs and tissues. Adiponectin and leptin are secreted primarily by adi-
pocytes while the stromovascular tissue surrounding fat secretes tumor necrosis factor—alpha
(TNF-α) and macrophages secrete resistin [11]. These adipokines have been proposed as links
between adiposity and insulin resistance, glucose dysregulation, and cardiovascular disease
[12]. Laboratory studies have shown that, apart from their direct influences on glucose and
lipid metabolism, these adipose-derived molecules exert direct actions on vascular cells as well
as cardiomyocytes. Recently, investigators showed that higher leptin was possibly associated
with greater RV mass and larger RVEDV in healthy women [10, 13]. Additionally, a recent
study in the MESA cohort found that higher levels of leptin are associated with more favorable
values of several measures of LV structure and function [14]. Collectively, these findings sug-
gest that adipokines are associated with the accumulation of triglycerides in nonadipose tissue
compartments, such as the LV and potentially the RV [14, 15].
In this study we aimed to determine the associations between four adipokines (leptin, resis-
tin, TNF-α, and adiponectin) with measures of RV structure and function measured by cardiac
magnetic resonance imaging (MRI) among a large, nationally representative multi-ethnic adult
population without clinical cardiovascular disease.
Adipokines and the Right Ventricle
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Methods
Subjects
The MESA is a multicenter prospective cohort study designed to investigate the prevalence,
correlates, and progression of subclinical cardiovascular disease in Caucasians, African-Ameri-
cans, Hispanics, and Chinese-Americans without clinical cardiovascular disease at baseline
[16]. In 2000–2002, MESA recruited 6,814 men and women aged 45–84 years old from six
communities in the United States: Forsyth County, North Carolina; Northern Manhattan and
the Bronx, New York; Baltimore City and Baltimore County, Maryland; St. Paul, Minnesota;
Chicago, Illinois; and Los Angeles, California. Exclusion criteria included clinical cardiovascu-
lar disease (physician diagnosis of heart attack, stroke, transient ischemic attack, heart failure,
angina, current atrial fibrillation, any cardiovascular procedure), weight> 136 kilograms (kgs)
(300 pounds), pregnancy, or impediment to long-term participation.
The study sample for the current study utilizes data from overlapping ancillary studies from
the MESA. Specifically, of the 6,814 MESA participants, 5,098 had cardiac MRIs at baseline, of
which 5,004 were interpretable for LV measures. The MESA-RV Study is an ancillary study
that selected 4,634 of the interpretable LV MRI scans (without regard to age, sex, or race) for
evaluation of RV structure and function. Of these, 4,424 had interpretation attempted and
4,204 were available and interpretable for RV morphology. The MESA Body Composition
ancillary study analyzed stored venous blood for the adipokines adiponectin, leptin, resistin
and TNF-α on a random sample of 1,964 participants from the baseline MESA cohort. Of
these, 1,267 participants had interpretable RV MRI image data and complete covariate data,
comprising the final sample for the current study.
The protocols of MESA and all studies described herein were approved by the Institutional
Review Boards of collaborating institutions and the National Heart Lung and Blood Institute
(NHLBI).
Data Collection
Race and ethnicity was self-reported during the baseline MESA exam according to 2000 US
Census criteria as race (Caucasian, African-American, Chinese) and ethnicity (Hispanic or
non-Hispanic). Standard questionnaires were used to ascertain smoking status (classified as
never, former, or current) and pack years. Height was measured to the nearest 0.1 cm with the
subject in stocking feet. Weight was measured to the nearest 0.5 kg with the subject in light
clothing using a balanced scale. Body mass index (BMI) was calculated [Weight (kg)/ Height
(m)2]. Waist circumference was measured to the nearest 0.1 cm using a steel measuring tape
(standard 4 ounce tension) from midway between the last rib and the iliac crest at normal
breathing. Hip circumference was measured to the nearest 0.1 cm from the largest diameter of
the hip. Resting blood pressure was measured three times using the Dinamap Monitor PRO
100 (Critikon, Tampa, FL) automated oscillometric device, and the average of the last two mea-
surements was used. Hypertension was defined as systolic blood pressure 140 mmHg, dia-
stolic blood pressure 90 mmHg or self-reported hypertension and current use of anti-
hypertensive medication. Detailed methods for these measures are published elsewhere [17].
Spirometry measures were available for a subset of participants included in a MESA ancil-
lary study. The MESA-Lung Study enrolled 3,965 of 4,484 eligible MESA participants who had
consented to genetic analyses, undergone baseline measures of endothelial function, and
attended an examination (with over-sampling of Chinese participants) in 2004 to 2006, of
whom 1,063 were included for these analyses [18].
Adipokines and the Right Ventricle
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Cardiac Magnetic Resonance Imaging Measures. The cardiac MRI protocol and meth-
ods for interpretation of LV and RV parameters have been previously reported [19, 20]. All
imaging was performed with 1.5-T magnets with a 4-element phased-array surface coil posi-
tioned anteriorly and posteriorly and ECG gating. Imaging consisted of fast gradient echo cine
images with temporal resolution 50 milliseconds. Cardiac MRI examinations were transmit-
ted to the reading center at Johns Hopkins University in Baltimore, MD, with the digital imag-
ing and communications in medicine (DICOM) transfer protocol. Image analysis was done on
Windows workstations with QMASS software (version 4.2; Medis, the Netherlands). Images
were magnified to 250%. Image contrast was set to 55; image brightness was set to 55; and win-
dow width and level were set with the auto function in QMASS to minimum and maximum
pixel values of 0 and 238, respectively.
The endocardial and epicardial borders of the RV were traced manually on the short-axis
cine images at the end-systolic and end-diastolic phases. Full visualization of the correct place-
ment of RV contours relied on evaluation of cine images to determine the demarcation between
the right atrium and the RV. Contours were modified at basal slices of the heart by careful iden-
tification of the tricuspid valve so as to exclude the right atrium and to avoid overestimation of
the volumes. The outflow tract was included in the RV volume.
RVEDV and RVESV were calculated using Simpson's rule by summation of areas on each
slice multiplied by the sum of slice thickness and image gap. RV mass was determined at end-
diastole as the difference between end-diastolic epicardial and endocardial volumes multiplied
by the specific gravity of the heart (1.05 g/cm3) [20]. RVSV was calculated by subtracting
RVESV from RVEDV; RVEF was calculated by dividing RVSV by RVEDV. The intrareader
intraclass correlation coefficient from random, blinded rereads of 229 scans for RV mass was
0.94 and for RVEDV and RVEF from 230 scans was 0.99 and 0.89. The interreader intraclass
correlation coefficients from random, blinded rereads of 240 scans for RV mass, RVEDV, and
RVEF were 0.89, 0.96, and 0.80, respectively.
Laboratory methods. Total and HDL cholesterol, triglycerides, and glucose levels were
measured from blood samples obtained after a 12-hour fast [21]. Diabetes was defined as fast-
ing glucose 126 mg/dL or use of hypoglycemic medication. Fasting glucose between 100–125
mg/dL was considered impaired fasting glucose. Stored fasting blood samples were analyzed to
provide levels of adiponectin, leptin, TNF-α and resistin. These adipokines were measured
using Bio-Rad Luminex flow cytometry (Millepore, Billerica, Massachusetts) at the Laboratory
for Clinical Biochemistry Research (University of Vermont, Burlington, Vermont). Average
analytical coefficients of variation across several control samples for these analytes ranged
from 6.0–13.0%.
Statistical Analysis
In the descriptive tables, continuous variables are described as means and standard deviations
and categorical variables are expressed as percentages. Each adipokine distribution was log
transformed to reduce skew and the impact of outliers. Multivariable linear regression models
were then used to assess the relationship of each of the adipokines with the five RV parameters:
RV mass, RVEDV, RVESV, RVSV and RVEF. We examined three specifications of our initial
model which included age, gender, race/ethnicity and either (1) height and weight, (2) BMI
(continuous), or (3) BMI categories. The choice of body anthropometry used in the model did
not affect the conclusions (i.e., the estimated regression coefficients). For the base model,
adjustment for height and weight separately was chosen as it avoided the assumptions made in
indexing the RV measures to certain parameters of body size (e.g., body surface area), while
accounting for differences in body size between participants. Additional covariates were chosen
Adipokines and the Right Ventricle
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based on (i) their independent p-values (less than 0.20 to avoid beta error), (ii) they impacted
the estimated coefficient of the independent variable (i.e., the adipokine of interest by at least
10% indicating confounding) or (iii) because of their known biological roles with the RV. The
fully adjusted model contained continuous measures of blood pressure, total cholesterol, HDL,
triglycerides, waist and hip circumference, an indicator for smoking history (current, past,
never), pack-years, diabetes mellitus, the use of hypertension medications, statin use and socio-
economic status (measured as highest level of educational attainment).
In the final model, adjustment for LV parameters was performed to (i) account for the con-
tribution of LV abnormalities to RV changes (for example, increased LV mass causing pulmo-
nary venous hypertension leading to increased RV mass), (ii) to better adjust for differences in
body size, and (iii) to examine RV-specific associations (rather than more general associations
with bi-ventricular morphology). These models when adjusted for the respective LV parame-
ters facilitate a better understanding of whether the associations are right ventricle specific. To
determine if the associations between the adipokines and RV measures were non-linear, we
estimated unadjusted and adjusted generalized additive models (GAM). A subset of the study
sample with available spirometry fromMESA-Lung was also examined in further sensitivity
analyses.
Statistical significance was defined as P< 0.05. As each adipokine analysis was considered
an independent hypothesis, there was no correction made for multiple comparisons [22]. Anal-
yses were performed using STATA 13.0 (StataCorp, College Station, Texas).
Results
A total of 1,267 MESA participants participated in both the RV and adipokine ancillary studies,
representing 18.9% of all MESA participants (Table 1). The mean age of the study sample was
61.3 ± 9.5 years and half were female. The mean BMI was 27.6 ± 4.7.kg/m2 and 40.5% were
Caucasian, 26.0% were Hispanic, 19.0% were African American and 14.5% were Chinese
American. Half were life-long non-smokers and 11.0% had diabetes mellitus, similar to those
not included in this sub-study. The mean RV mass, RVEDV, RVESV, stroke volume and ejec-
tion fraction were 21.3 grams, 126.9 mL, 38.3 mL, 88.6 mL and 70.4%, respectively (Table 2).
Pearson’s correlations between the RV and LV was the following: end-diastolic mass = 0.62,
end-diastolic volume = 0.82, end-systolic volume = 0.64, stroke volume = 0.79, and ejection
fraction = 0.47.
To normalize the adipokine distributions in the multivariable linear regression models the
adipokine values were natural log-transformed (Table 3). Higher leptin levels were associated
with significantly lower levels of RV mass, RVEDV, RVESV and stroke volume after adjust-
ment for age, gender, race, height and weight. Leptin levels were not associated with RVEF.
These associations were somewhat attenuated but still significant after additional adjustment
for education, blood pressure, cholesterol levels, triglycerides, current smoking status and
smoking history (pack years), diabetes mellitus, waist & hip circumference, glucose levels, and
indicator variables for statin use or hypertension medication. These observed associations
between leptin and the RV were no longer significant after adjustment for the corresponding
LV measures of function and morphology (Table 3). These results were not quantitatively dif-
ferent after adjustment for measures of lung-function derived from the spirometry exam (not
shown). In addition, other covariates, including C-reactive protein, creatinine, estimated glo-
merular filtration rate and alcohol use, did not show evidence of confounding nor did they
improve model fit. Examination of plots from GAMmodels did not show evidence of non-lin-
ear associations. There were no significant interactions between any of the adipokines with age,
gender or race/ethnicity or between leptin and BMI.
Adipokines and the Right Ventricle
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Regression analyses showed that there were no significant associations between adiponectin,
resistin and TNF-α and RV measures with one exception. Adiponectin showed a positive asso-
ciation with RVEF in the LV adjusted models, but not without accounting for LVEF. GAM
plots did not reveal significant non-linearity in the associations of any of the adipokines with
RV parameters.
Discussion
This is the first study to examine the association between adipokines and the RV, contributing
to the growing literature supporting the relationship of adipokines with cardiovascular
Table 1. Characteristics of the study sample. Participant characteristics are summarized as mean (SD) or
n (%).
Excluded Study sample
n = 5,547 n = 1,267
Age, years 62.34 (10.4) 61.32 (9.5)
Female 2966 (53.7%) 635 (49.3%)
Race/ethnicity
Caucasian 2101 (38.0%) 521 (40.5%)
Chinese American 616 (11.1%) 187 (14.5%)
African American 1649 (29.8%) 244 (19.0%)
Hispanic 1161 (21.0%) 335 (26.0%)
Educational attainment
No high school degree 1001 (18.2%) 224 (17.4%)
High school degree 1003 (18.2%) 233 (18.1%)
Some college, no bachelors 1580 (28.7%) 357 (27.8%)
Bachelors or graduate 1921 (34.9%) 472 (36.7%)
Height, cm 166.23 (10.0) 166.90 (9.9)
Weight, lbs 174.11 (39.0) 170.17 (34.6)
BMI, kg/m2 28.50 (5.6) 27.63 (4.7)
Systolic blood pressure, mmHg 126.79 (21.5) 125.74 (21.3)
Diastolic blood pressure, mmHg 71.74 (10.3) 72.67 (10.2)
Total cholesterol, mg/dL 193.93 (36.2) 195.12 (33.6)
HDL cholesterol, mg/dL 50.95 (14.8) 51.01 (15.0)
Triglycerides, mg/dL 131.10 (90.8) 133.70 (79.7)
Cigarette smoking status
Never 2741 (49.8%) 677 (52.6%)
Former 2039 (37.0%) 448 (34.8%)
Current 726 (13.2%) 161 (12.5%)
Diabetes mellitus status
Normal 4020 (73.0%) 972 (75.8%)
IGF 769 (14.0%) 170 (13.3%)
Untreated diabetes 141 (2.6%) 38 (3.0%)
Treated diabetes 577 (10.5%) 103 (8.0%)
Glucose, mg/dL 97.72 (31.2) 95.92 (26.0)
Smoking history, pack years 11.38 (21.1) 11.45 (26.8)
Resistin, pg/mL 17284.71 (11019.3) 15901.88 (6521.2)
Adiponectin, ng/mL 20290.98 (12752.3) 20944.11 (13378.1)
Leptin, pg/mL 23056.31 (22522.5) 19596.30 (22134.6)
TNF-α, pg/mL 6.51 (15.4) 5.61 (8.4)
doi:10.1371/journal.pone.0136818.t001
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function and disease [11, 15, 23]. In this cross-sectional study of a large cohort of individuals
from four distinct ethnic groups from across the United States, higher levels of leptin were
associated with significantly lower RV mass, RVEDV, RVESV, and RVSV independent of
anthropometric measures and other confounders, but not after accounting for LV function.
Conversely, there were no persistent associations between these RV measures and adiponectin,
resistin or TNF-α, which also align with recent findings in the LV in the MESA cohort [14].
Plasma leptin is produced by adipose tissue and regulates body fat stores and food intake.
Leptin has pleitropic actions in the central nervous system and studies have shown both
Table 3. Adjusted linear regression coefficients and 95% confidence intervals of the association between adipokines and right ventricular struc-
ture and function. Model 1: Adjusted for age, gender, race, height and weight. Model 2: Model 1 + education, systolic and diastolic blood pressure, total &
HDL cholesterol, triglycerides, current smoking status and pack years, diabetes, waist & hip circumference, glucose, and currently taking statins or hyperten-
sion medication. Model 3: Model 2 + respective LV measure. Abbreviations: RV = right ventricle, LV = left ventricle, LVEDV = left ventricular end-diastolic vol-
ume, LVESV = left ventricular end-systolic volume, LVEF = left ventricular ejection fraction, LVSV = left ventricular stroke volume.
Log Leptin, pg/mL Log Resistin, pg/mL Log TNF-α, pg/mL Log Adiponectin, ng/mL
RV End-Diastolic Mass (g)
Model 1 -0.34 (-0.56, -0.13) p = 0.002 0.03 (-0.42, 0.49) p = 0.88 0.06 (-0.26, 0.39) p = 0.70 0.06 (-0.28, 0.40) p = 0.73
Model 2 -0.30 (-0.51, -0.08) p = 0.008 0.02 (-0.44, 0.48) p = 0.95 0.11 (-0.22, 0.43) p = 0.52 -0.09 (-0.45, 0.26) p = 0.62
Model 2 + LV Mass -0.13 (-0.34, 0.08) p = 0.21 0.05 (-0.38, 0.49) p = 0.81 0.01 (-0.30, 0.32) p = 0.94 -0.15 (-0.48, 0.19) p = 0.39
RV End-Diastolic Volume (mL)
Model 1 -4.14 (-5.58, -2.70) p < 0.001 -1.82 (-4.90, 1.26) p = 0.25 -0.80 (-3.00, 1.41) p = 0.48 1.81 (-0.49, 4.10) p = 0.12
Model 2 -3.81 (-5.25, -2.36) p < 0.001 -1.77 (-4.84, 1.31) p = 0.26 -0.53 (-2.71, 1.64) p = 0.63 0.90 (-1.49, 3.28) p = 0.46
Model 2 + LVEDV -0.75 (-1.81, 0.30) p = 0.16 -0.49 (-2.68, 1.71) p = 0.66 -0.30 (-1.85, 1.25) p = 0.71 -0.30 (-2.00, 1.39) p = 0.73
RV End-Systolic Volume (mL)
Model 1 -1.52 (-2.26, -0.78) p < 0.001 -0.78 (-2.35, 0.80) p = 0.33 0.35 (-0.78, 1.48) p = 0.54 -0.03 (-1.20, 1.15) p = 0.96
Model 2 -1.44 (-2.20, -0.69) p < 0.001 -0.84 (-2.43, 0.76) p = 0.31 0.42 (-0.71, 1.54) p = 0.47 -0.21 (-1.44, 1.03) p = 0.74
Model 2 + LVESV -0.66 (-1.33, 0.02) p = 0.05 -0.93 (-2.34, 0.48) p = 0.20 0.11 (-0.89, 1.11) p = 0.83 -0.83 (-1.93, 0.26) p = 0.14
RV Stroke Volume (mL)
Model 1 -2.62 (-3.68, -1.55) p < 0.001 -1.04 (-3.31, 1.23) p = 0.37 -1.15 (-2.77, 0.48) p = 0.17 1.84 (0.15, 3.53) p = 0.03
Model 2 -2.36 (-3.43, -1.30) p < 0.001 -0.93 (-3.19, 1.33) p = 0.42 -0.95 (-2.54, 0.65) p = 0.25 1.10 (-0.65, 2.85) p = 0.22
Model 2 + LVSV -0.51 (-1.26, 0.25) p = 0.19 0.59 (-1.00, 2.17) p = 0.46 -0.17 (-1.29, 0.95) p = 0.77 0.91 (-0.31, 2.14) p = 0.14
RV Ejection Fraction (%)
Model 1 0.05 (-0.36, 0.46) p = 0.82 0.22 (-0.65, 1.08) p = 0.63 -0.37 (-0.99, 0.25) p = 0.24 0.43 (-0.22, 1.07) p = 0.19
Model 2 0.06 (-0.36, 0.48) p = 0.78 0.27 (-0.61, 1.15) p = 0.55 -0.35 (-0.97, 0.27) p = 0.27 0.38 (-0.30, 1.06) p = 0.27
Model 2+ LVEF -0.03 (-0.42, 0.35) p = 0.86 0.52 (-0.29, 1.33) p = 0.21 -0.11 (-0.68, 0.47) p = 0.72 0.63 (0.00, 1.25) p = 0.05
doi:10.1371/journal.pone.0136818.t003
Table 2. Left and right ventricle measures. LV = left ventricle, RV = right ventricle, SD = standard
deviation.
Mean SD Min Max
LV end-diastolic mass, g 146.6 37.5 67.0 317.0
LV end-diastolic volume, mL 128.2 30.3 56.0 257.2
LV end-systolic volume, mL 40.4 16.2 10.1 144.1
LV stroke volume, mL 87.7 19.2 15.2 182.7
LV ejection fraction, % 69.1 7.3 18.9 87.3
RV end-diastolic mass, g 21.3 4.4 10.1 44.7
RV end-diastolic volume, mL 126.9 31.5 53.5 254.6
RV end-systolic volume, mL 38.3 14.9 4.9 100.1
RV stroke volume, mL 88.6 20.4 38.3 178.3
RV ejection fraction, % 70.4 6.5 47.1 91.3
doi:10.1371/journal.pone.0136818.t002
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hypertrophic and cardioprotective actions on the LV myocardium. Some animal models have
shown that leptin increases LV hypertrophy [24] whereas others showed that leptin inhibits
the hypertrophic response [25, 26]. Human studies have also reported conflicting roles of leptin
on cardiac myocyte mass. While some studies have shown a positive relationship between
plasma leptin levels and LV mass [10, 13, 27], other studies suggest an inverse relationship as
shown in our study in the RV. Lieb et al. found that higher leptin levels were associated with
lower LV mass in community-based older adults [28, 29]. Similar findings were demonstrated
in a population-based sample of 410 adults from Spain [30] and in overweight sedentary post-
menopausal women [31]. These data correspond with other findings in obese adults (showing
increased ventricular mass), which is characterized by leptin resistance [28, 29] and correspond
with the obesity-related increases in RV mass shown in the MESA cohort [8, 32].
It appeared that leptin had a similar relationship with both LV and RV mass, since the asso-
ciation was not present after additional adjustment for LV mass. It is also possible that leptin
affected the RV through changes in LV mass and left-ventricular end-diastolic pressure. The
MESA cohort includes individuals free of clinical cardiovascular disease, which might explain
the inverse associations with RV mass, whereas studies showing adverse effects of leptin are
from patients with clinical cardiovascular disease. Adiponectin conversely showed a positive
association with RVEF but not RV mass in the LV adjusted models. Adiponectin has been
shown to exert vasculoprotective, anti-atherosclerotic, and anti-thrombotic effects through
modulation of endothelial cells, smooth muscle cells, macrophages, and platelets [33]. Adipo-
nectin has antihypertrophic effects and protects against ischemia-reperfusion injury in labora-
tory models [23]. Likewise, reduced plasma levels of adiponectin have been reported in
diabetics and patients with coronary artery disease and increased carotid intima-media thick-
ness. Taken together, the cardiovascular findings with adiponectin appear to be complex and
not very well understood, showing an inverse relationship in healthy younger cohorts but a
positive association with older cohorts or cohorts with prevalent disease [34–37].
There are several limitations to our study. Foremost, cross-sectional studies are unable to
establish temporality, and thus casual inferences cannot be made. Additionally, not all MESA
participants were able to tolerate cardiac MRI and some readings were uninterpretable. How-
ever, there were only slight differences between those individuals included in our study sample
and those not (Table 1). A strength of this study is that we are uniquely able to examine adults
over a spectrum of ages and of various races and ethnicities, increasing generalizability. In par-
ticipants without clinical cardiovascular disease, cardiac MRI may be more sensitive for detec-
tion of subtle cardiovascular changes than other methods, such as echocardiography or right
heart catheterization. To our knowledge, there is no other large population-based multi-ethnic
cohort that has completed MRI-based RV measures.
In conclusion, the associations between RV structure and function in clinical cardiovascular
disease-free individuals observed in this study complement the associations shown between
adipokines and LV structure and function in diseased and healthy patients [14]. Yet, the under-
standing of the mechanisms linking adipokines to healthy vascular function is still inchoate
and has to date largely been focused on leptin. This analysis adds to the growing literature on
these mediators released from adipose tissue and how they modulate cardiac and vascular pro-
cesses in cardiovascular disease free individuals.
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